Format

Send to

Choose Destination
Ann Nucl Med. 2010 Jan;24(1):21-7. doi: 10.1007/s12149-009-0322-9. Epub 2009 Nov 25.

18F-FDG PET imaging of progressive massive fibrosis.

Author information

1
Department of Diagnostic Radiology, Yongin Severance Hospital, Research Institute of Radiological Science, Yonsei University College of Medicine, Yongin, Kyunggi-Do, Republic of Korea.

Abstract

PURPOSE:

This study was to evaluate (18)F-FDG PET features of progressive massive fibrosis (PMF) and to determine the ability of FDG PET to differentiate pure PMF from PMF-associated lung cancer.

METHODS:

(18)F-FDG PET and chest computed tomography (CT) scans were performed in 9 patients with pneumoconiosis and PMF. Patients who showed active pulmonary tuberculosis on CT scan were excluded. Pure PMF was confirmed via either fine needle aspiration biopsy (n = 6) or 12 months follow-up CT scan (n = 3). CT features and PET findings were evaluated for distribution of fibrotic masses, consolidations, and nodules on CT scan and mean and maximum standardized uptake values (SUVs) of abnormalities depicted on PET scan.

RESULTS:

14 masses were detected from nine patients. On chest CT scan, PMF masses were noted with surrounding small nodules and distortion of parenchyma. The size of the lesions ranged from 1.2 to 6.4 cm in maximum diameter. FDG PET scans identified metabolically active lesions in all patients. Maximal SUV ranged from 3.1 to 14.6 and mean SUV ranged from 1.4 to 8.5.

CONCLUSION:

FDG PET can identify PMF lesions as hypermetabolic lesions even without associated malignancy or tuberculosis. Therefore, it might have a limited role in the diagnosis of PMF with possible concurrent granulomatous inflammation or lung cancer.

PMID:
19937406
DOI:
10.1007/s12149-009-0322-9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center